Sunovion inks COPD drug licensing deal

21 December 2016

USA-based Sunovion Pharmaceuticals has signed an exclusive license agreement for the US commercialization rights to three approved medicines, Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder, Seebri Neohaler (glycopyrrolate) inhalation powder and Arcapta Neohaler (indacaterol) inhalation powder, with the drugs’ developer, Swiss pharma giant Novartis (NOVN: VX).

Novartis will continue to manufacture these medicines for Sunovion, and to commercialize them outside of the USA. The UK’s Vectura receives royalty revenue from Novartis for these products, which utilize Vectura's inhaler technology.

The drugs are indicated for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). With this transaction, Sunovion, a subsidiary of Japanese pharma company Sumitomo Dainippon (TYO: 4506), now has the broadest COPD portfolio in the US, providing handheld and nebulized treatment options for people with all stages of COPD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK